The Efficacy of a Brief, Altruism-Eliciting Video Intervention in Enhancing COVID-19 Vaccination Intentions Among a Population-Based Sample of Younger Adults: Randomized Controlled Trial.

COVID-19 altruism digital health digital intervention health information health intervention health promotion online health prosocial motives public health randomized controlled trial vaccination vaccine hesitancy video intervention web survey younger adults youth

Journal

JMIR public health and surveillance
ISSN: 2369-2960
Titre abrégé: JMIR Public Health Surveill
Pays: Canada
ID NLM: 101669345

Informations de publication

Date de publication:
30 05 2022
Historique:
received: 15 02 2022
accepted: 07 05 2022
revised: 28 04 2022
pubmed: 12 5 2022
medline: 3 6 2022
entrez: 11 5 2022
Statut: epublish

Résumé

High COVID-19 vaccine uptake is crucial to containing the pandemic and reducing hospitalizations and deaths. Younger adults (aged 20-39 years) have demonstrated lower levels of vaccine uptake compared to older adults, while being more likely to transmit the virus due to a higher number of social contacts. Consequently, this age group has been identified by public health authorities as a key target for vaccine uptake. Previous research has demonstrated that altruistic messaging and motivation is associated with vaccine acceptance. This study had 2 objectives: (1) to evaluate the within-group efficacy of an altruism-eliciting short, animated video intervention in increasing COVID-19 vaccination intentions amongst unvaccinated Canadian younger adults and (2) to examine the video's efficacy compared to a text-based intervention focused exclusively on non-vaccine-related COVID-19 preventive health measures. Using a web-based survey in a pre-post randomized control trial (RCT) design, we recruited Canadians aged 20-39 years who were not yet vaccinated against COVID-19 and randomized them in a 1:1 ratio to receive either the video intervention or an active text control. The video intervention was developed by our team in collaboration with a digital media company. The measurement of COVID-19 vaccination intentions before and after completing their assigned intervention was informed by the multistage Precaution Adoption Process Model (PAPM). The McNemar chi-square test was performed to evaluate within-group changes of vaccine intentions. Exact tests of symmetry using pairwise McNemar tests were applied to evaluate changes in multistaged intentions. Between-group vaccine intentions were assessed using the Pearson chi-square test postintervention. Analyses were performed on 1373 participants (n=686, 50%, in the video arm, n=687, 50%, in the text arm). Within-group results for the video intervention arm showed that there was a significant change in the intention to receive the vaccine (χ Although the video intervention was limited in its effect on those who had firmly decided not to vaccinate, our study demonstrates that prosocial and altruistic messages could increase COVID-19 vaccine uptake, especially when targeted to younger adults who are undecided or unengaged regarding vaccination. This might indicate that altruistic messaging provides a "push" for those who are tentative toward, or removed from, the decision to receive the vaccine. The results of our study could also be applied to more current COVID-19 vaccination recommendations (eg, booster shots) and for other vaccine-preventable diseases. ClinicalTrials.gov NCT04960228; https://clinicaltrials.gov/ct2/show/NCT04960228.

Sections du résumé

BACKGROUND
High COVID-19 vaccine uptake is crucial to containing the pandemic and reducing hospitalizations and deaths. Younger adults (aged 20-39 years) have demonstrated lower levels of vaccine uptake compared to older adults, while being more likely to transmit the virus due to a higher number of social contacts. Consequently, this age group has been identified by public health authorities as a key target for vaccine uptake. Previous research has demonstrated that altruistic messaging and motivation is associated with vaccine acceptance.
OBJECTIVE
This study had 2 objectives: (1) to evaluate the within-group efficacy of an altruism-eliciting short, animated video intervention in increasing COVID-19 vaccination intentions amongst unvaccinated Canadian younger adults and (2) to examine the video's efficacy compared to a text-based intervention focused exclusively on non-vaccine-related COVID-19 preventive health measures.
METHODS
Using a web-based survey in a pre-post randomized control trial (RCT) design, we recruited Canadians aged 20-39 years who were not yet vaccinated against COVID-19 and randomized them in a 1:1 ratio to receive either the video intervention or an active text control. The video intervention was developed by our team in collaboration with a digital media company. The measurement of COVID-19 vaccination intentions before and after completing their assigned intervention was informed by the multistage Precaution Adoption Process Model (PAPM). The McNemar chi-square test was performed to evaluate within-group changes of vaccine intentions. Exact tests of symmetry using pairwise McNemar tests were applied to evaluate changes in multistaged intentions. Between-group vaccine intentions were assessed using the Pearson chi-square test postintervention.
RESULTS
Analyses were performed on 1373 participants (n=686, 50%, in the video arm, n=687, 50%, in the text arm). Within-group results for the video intervention arm showed that there was a significant change in the intention to receive the vaccine (χ
CONCLUSIONS
Although the video intervention was limited in its effect on those who had firmly decided not to vaccinate, our study demonstrates that prosocial and altruistic messages could increase COVID-19 vaccine uptake, especially when targeted to younger adults who are undecided or unengaged regarding vaccination. This might indicate that altruistic messaging provides a "push" for those who are tentative toward, or removed from, the decision to receive the vaccine. The results of our study could also be applied to more current COVID-19 vaccination recommendations (eg, booster shots) and for other vaccine-preventable diseases.
TRIAL REGISTRATION
ClinicalTrials.gov NCT04960228; https://clinicaltrials.gov/ct2/show/NCT04960228.

Identifiants

pubmed: 35544437
pii: v8i5e37328
doi: 10.2196/37328
pmc: PMC9153910
doi:

Substances chimiques

COVID-19 Vaccines 0
Vaccines 0

Banques de données

ClinicalTrials.gov
['NCT04960228']

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e37328

Subventions

Organisme : CIHR
Pays : Canada

Informations de copyright

©Patricia Zhu, Ovidiu Tatar, Gabrielle Griffin-Mathieu, Samara Perez, Ben Haward, Gregory Zimet, Matthew Tunis, Ève Dubé, Zeev Rosberger. Originally published in JMIR Public Health and Surveillance (https://publichealth.jmir.org), 30.05.2022.

Références

Vaccine. 2021 Aug 23;39(36):5116-5128
pubmed: 34340856
Nat Med. 2021 Feb;27(2):225-228
pubmed: 33082575
Health Psychol. 2013 Sep;32(9):978-85
pubmed: 24001248
Proc Natl Acad Sci U S A. 2020 Jun 30;117(26):14890-14899
pubmed: 32541033
PLoS One. 2021 Oct 27;16(10):e0258432
pubmed: 34705834
J Behav Med. 2019 Jun;42(3):381-391
pubmed: 30387010
Psychol Med. 2002 Aug;32(6):959-76
pubmed: 12214795
BMC Public Health. 2021 Jun 25;21(1):1223
pubmed: 34172016
J Affect Disord. 2020 Dec 1;277:55-64
pubmed: 32799105
Biomed Res Int. 2016;2016:6870984
pubmed: 27725940
Int J Infect Dis. 2020 Sep;98:180-186
pubmed: 32562846
Hum Vaccin Immunother. 2019;15(7-8):1803-1814
pubmed: 30735442
Vaccine. 2017 May 9;35(20):2676-2684
pubmed: 28408120
J Health Soc Behav. 2016 Sep;57(3):390-406
pubmed: 27601412
Vaccines (Basel). 2021 Nov 15;9(11):
pubmed: 34835254
PLoS One. 2016 Jul 26;11(7):e0159780
pubmed: 27459237
J Epidemiol Community Health. 2005 May;59(5):342-5
pubmed: 15831678
BMJ Glob Health. 2021 Sep;6(9):
pubmed: 34593513
Vaccine. 2015 Jan 9;33(3):459-64
pubmed: 25499651
Curr Opin Psychol. 2022 Apr;44:124-129
pubmed: 34627110
Vaccine. 2017 Aug 24;35(36):4713-4721
pubmed: 28757059
Vaccine. 2021 Jun 11;39(26):3473-3479
pubmed: 34023134
Health Educ Behav. 2007 Oct;34(5):777-92
pubmed: 17200094
BMC Public Health. 2021 Sep 16;21(1):1686
pubmed: 34530804
Vaccines (Basel). 2021 Oct 21;9(11):
pubmed: 34835156
Psychol Methods. 2012 Sep;17(3):437-55
pubmed: 22506584
Psychol Sci Public Interest. 2017 Dec;18(3):149-207
pubmed: 29611455
Vaccines (Basel). 2021 Sep 28;9(10):
pubmed: 34696208
Soc Sci Med. 2022 Jan;292:114195
pubmed: 34602309
N Engl J Med. 2021 Oct 28;385(18):1718-1720
pubmed: 34496200
JAMA. 2021 Jun 22;325(24):2435-2436
pubmed: 34076690
Prev Med. 2018 Nov;116:203-210
pubmed: 30267734
Front Psychol. 2021 Apr 15;12:609893
pubmed: 33935865
Psychol Sci. 2012 Sep 1;23(9):1008-15
pubmed: 22810166
PLoS One. 2021 Feb 19;16(2):e0246941
pubmed: 33606782
Front Immunol. 2021 Jun 14;12:558270
pubmed: 34194418
J Pers Assess. 2009 Jan;91(1):62-71
pubmed: 19085285
Int J Soc Psychiatry. 2020 Jun;66(4):317-320
pubmed: 32233719
Hum Vaccin Immunother. 2013 Aug;9(8):1763-73
pubmed: 23584253
J Microbiol Immunol Infect. 2021 Feb;54(1):12-16
pubmed: 32425996
Can J Public Health. 2021 Jun;112(3):363-375
pubmed: 33761109
Nature. 2021 Sep;597(7876):404-409
pubmed: 34340242
JMIR Public Health Surveill. 2021 Dec 23;7(12):e30424
pubmed: 34779784
J R Soc Interface. 2012 Sep 7;9(74):2234-43
pubmed: 22496100
J Clin Epidemiol. 2010 Aug;63(8):e1-37
pubmed: 20346624

Auteurs

Patricia Zhu (P)

Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.
Department of Psychiatry, McGill University, Montreal, QC, Canada.

Ovidiu Tatar (O)

Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.
Research Center, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.

Gabrielle Griffin-Mathieu (G)

Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.

Samara Perez (S)

Cedars Cancer Center, McGill University Health Center, Montreal, QC, Canada.
Department of Oncology, McGill University, Montreal, QC, Canada.

Ben Haward (B)

Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.

Gregory Zimet (G)

Division of Adolescent Medicine, Indiana University School of Medicine, Indianapolis, IN, United States.

Matthew Tunis (M)

National Advisory Committee on Immunization Secretariat, Centre for Immunization Readiness, Public Health Agency of Canada, Ottawa, ON, Canada.

Ève Dubé (È)

Faculty of Social Sciences; Anthropology, University of Laval, Québec, QC, Canada.

Zeev Rosberger (Z)

Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.
Department of Psychiatry, McGill University, Montreal, QC, Canada.
Department of Oncology, McGill University, Montreal, QC, Canada.
Department of Psychology, McGill University, Montreal, QC, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH